Sign in Subscribe
Stock offerings

Thiogenesis Therapeutics Corp. Announces Private Placement of $1.5 Million to Fund Mitochondrial Encephalopathy Lactic Acidosis and Stroke (MELAS) Clinical Trial Expenses

Strategic Insights

— 1 min read

Thiogenesis Therapeutics Corp. has announced a non-brokered private placement of $1.5 million to fund the company's Mitochondrial Encephalopathy Lactic Acidosis and Stroke (MELAS) clinical trial expenses, as well as the creation and purchase of additional TTI-0102 for future clinical trials.

Key Takeaways:

  • Thiogenesis Therapeutics Corp. will undertake a non-brokered private placement of 2,000,000 common shares at a price of $0.75 per share for gross proceeds of $1.5 million.
  • The offering is subject to the approval of the TSX Venture Exchange and is expected to close as soon as practicable.
  • The proceeds from the offering will be used to cover MELAS clinical trial expenses, create and purchase additional TTI-0102 for future clinical trials, and for general working capital.
  • Thiogenesis' lead product candidate, TTI-0102, is a prodrug that acts as a precursor to the thiol compound cysteamine, which has the potential to address oxidative stress and restore mitochondrial function.
  • Thiogenesis seeks to develop TTI-0102 to address the challenges of earlier thiol-based drugs, including their short half-life, adverse side effects, and dosing limitations.
  • The company has an active Phase 2 clinical trial in MELAS and plans to initiate clinical trials in Leigh syndrome spectrum, Rett syndrome, and pediatric Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Statistics:

  • 2,000,000 common shares will be issued at $0.75 per share for gross proceeds of $1.5 million.
  • The offering is expected to drive the development of TTI-0102, with the potential to improve the treatment of serious pediatric diseases with unmet medical needs.
  • Thiogenesis Therapeutics Corp. is a clinical-stage biopharmaceutical company with operations based in San Diego, CA.

Sources:

  • Newsfile Corp. - July 17, 2025
  • Thiogenesis Therapeutics Corp. press release (no date, but referenced in the Newsfile Corp. release)

Read more